Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review.

ABSTRACT:

Background

Effective systemic treatment of non-clear cell renal carcinoma (nccRCC) is still an unmet clinical need, with few studies to support an evidence-based approach. To date, the only recommended standard first-line treatment is sunitinib. Pazopanib may also be used in nccRCC but its place in therapy is not clearly established. It has comparable efficacy and better tolerability than sunitinib in clear cell renal carcinoma. Our objective was to review the use of pazopanib in metastatic nccRCC.

Methods

We conducted a systematic review according to PRISMA guidelines. Any type of study reporting the use of pazopanib in metastatic renal cell carcinoma including cases with non-clear cell histology was eligible.

Results

In all, 15 studies were included in our analysis,

SUBMITTER: Bersanelli M 

PROVIDER: S-EPMC7278098 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature